NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage
biopharmaceutical company developing novel oncology therapeutics, announced today that it has initiated its rolling submission of a
Biologics License Application (BLA) for SL-401 to the U.S. Food and Drug Administration (FDA). SL-401 is a targeted therapy
directed to CD123 that has been granted Breakthrough Therapy designation (BTD) by the FDA.
Ivan Bergstein, MD, CEO of Stemline, commented, “The start of our rolling BLA submission is a major milestone for Stemline and
the BPDCN patient community at large. If successful, SL-401 would be the first drug ever approved for BPDCN. Moreover, we believe
that SL-401 may have a transformative impact on the outcomes of patients with this lethal malignancy of high unmet medical need.
With this in mind, our clinical, regulatory, manufacturing, and commercial teams continue to work expeditiously to bring SL-401 to
patients as quickly as possible.”
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics. Stemline is
developing three clinical stage product candidates, SL-401, SL-801, and SL-701. SL-401 is a targeted therapy directed to the
interleukin-3 receptor (CD123) present on a range of malignancies. SL-401 has completed a pivotal trial in blastic plasmacytoid
dendritic cell neoplasm (BPDCN), for which it was granted breakthrough therapy designation (BTD). The pivotal trial met its primary
endpoint, and a rolling BLA submission has been initiated. SL-401 is also being evaluated in clinical trials in additional
indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and myeloma. SL-801
is a novel oral small molecule reversible inhibitor of XPO1 that is currently in a Phase 1 trial of patients with advanced solid
tumors; dose escalation is ongoing. SL-701, an immunotherapeutic, has completed a Phase 2 trial in patients with second-line
glioblastoma; data and next steps for the program are being evaluated.
Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the
success and timing of our BLA submission to the FDA; the success and timing of our clinical trials and preclinical studies for our
product candidates, including site initiation, institutional review board approval, scientific review committee approval, patient
accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities including the risk that the FDA or
other ex-U.S. national drug authority ultimately does not agree with our data, find our data supportive of approval, or
approve any of our product candidates; our plans to develop and commercialize our product candidates; market acceptance of our
products; reimbursement available for our products; our available cash and investments; our ability to obtain and maintain
intellectual property protection for our product candidates; our ability to obtain and maintain intellectual property protection
for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research
organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our
reports filed with the SEC. Any forward-looking statements set forth in this press release speak only as of the date of this press
release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the
date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
